单倍体相合造血干细胞移植治疗重型再生障碍性贫血进展

Advances in haploidentical hematopoietic stem cell transplantation for severe aplastic anemia

摘要: 同胞及无关供者全相合造血干细胞移植是治疗重型再生障碍性贫血(severe aplastic anemia，SAA)的一线治疗方案, 但该治疗供者匮乏，免疫抑制剂治疗部分无效、复发率高。单倍体相合造血干细胞移植近年发展迅速，疗效已接近全相合移植。单倍体相合造血干细胞移植扩大了移植供源，抓住了最佳治疗时机，使广大患者获益。本文综合目前国内外相关研究进展及临床治疗经验，对单倍体相合造血干细胞移植治疗SAA的研究进展进行综述。

Abstract: Matched sibling donor (MSD) or matched unrelated donor (MUD) hematopoietic stem cell transplantation is the frontline therapy for severe aplastic anemia. When MSD or MUD is not available, then intensive immunosuppressive therapy (IST) is indicated. However, IST has a high relapse rate due to lack of response. Haploidentical hematopoietic stem cell transplantation (Haplo-HSCT) has been developing so rapidly that they could now replace the transplantation from identical siblings with similar effcacy. The application of Haplo-HSCT terminate the era of donor shortage and bring beneft to the patients. This review will focus on the progress of the therapeutic effect of Haplo-HSCT in the treatment of SAA.